Brief: Bioarctic Says 29.3 Bln Yen In Q2 Sales Of Leqembi®
29/07/2026 11:02
BRIEF-Bioarctic Says 29.3 Bln Yen In Q2 Sales Of Leqembi® July 29 (Reuters) - BioArctic AB BIOAb.ST:
SALES OF LEQEMBI® TOTALED 29.3 BILLION YEN IN THE SECOND QUARTER 2026
Source text: ID:nWkrhPnf8
Further company coverage: [BIOAb.ST]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln